301230 泓博医药
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)1.4653.3739.19424.06021.022
总资产报酬率 ROA (%)1.1022.6987.22716.20615.254
投入资产回报率 ROIC (%)1.2222.9257.84718.61917.656

边际利润分析
销售毛利率 (%)23.77930.87536.87438.68842.566
营业利润率 (%)3.9507.64615.21119.33619.538
息税前利润/营业总收入 (%)4.0197.38813.68720.26723.127
净利润/营业总收入 (%)6.0127.68214.02816.41617.206

收益指标分析
经营活动净收益/利润总额(%)8.592107.78495.280100.76594.235
价值变动净收益/利润总额(%)52.14816.8900.6912.5513.017
营业外收支净额/利润总额(%)0.674-1.8540.105-0.501-0.138

偿债能力分析
流动比率 (X)3.6913.8249.2842.1542.782
速动比率 (X)3.2913.5038.7781.7912.052
资产负债率 (%)24.67624.85414.47637.53424.847
带息债务/全部投入资本 (%)3.4453.3692.50510.77613.777
股东权益/带息债务 (%)2,423.4092,473.3903,608.381672.302617.490
股东权益/负债合计 (%)305.251302.350590.777166.427302.468
利息保障倍数 (X)95.498-61.885-8.88519.7156.397

营运能力分析
应收账款周转天数 (天)66.66061.59364.13852.30862.091
存货周转天数 (天)59.56459.82258.26570.563107.857